Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114945 | 0.92 | RAB9A (0.56) | RAB9AKMT2ACYP1A2ADRA2AMAOA | |
| SCHEMBL3977427 | 0.86 | RAB9A (0.48) | RAB9AKMT2ACYP1A2ADRA2AMAOA | |
| SCHEMBL13612901 | 0.85 | RAB9A (0.50) | RAB9AKMT2ACYP1A2ADRA2AMAOA | |
| SCHEMBL3005279 | 0.85 | CYP1A2 (0.66) | RAB9AKMT2ACYP1A2ADRA2AMAOA | |
| SCHEMBL3978151 | 0.82 | RAB9A (0.67) | RAB9AKMT2ACYP1A2ADRA2AMAOA | |
| SCHEMBL3979949 | 0.81 | RAB9A (0.52) | RAB9AKMT2ACYP1A2ADRA2AMAOA | |
| SCHEMBL4980360 | 0.80 | RAB9A (0.48) | RAB9AKMT2ACYP1A2ADRA2AMAOA | |
| SCHEMBL3977433 | 0.80 | RAB9A (0.42) | RAB9AKMT2ACYP1A2ADRA2AMAOA | |
| SCHEMBL4984937 | 0.79 | RAB9A (0.50) | RAB9AKMT2ACYP1A2ADRA2AMAOA | |
| SCHEMBL16114898 | 0.79 | CA12 (0.47) | MAPTKDM4EALDH1A1GAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198284-B2 | Treatment of neurodegenerative disorders with thiourea compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-06-12 | — | — | US | disclosed |
| US-20090275596-A1 | Treatment of Neurodegenerative Disorders with Thiourea Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| EP-2056810-A2 | THIOUREA COMPOUNDS | National Health Research Institutes (TW) | 2009-05-13 | — | — | EP | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| WO-2008022204-A2 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275596-A1 | Treatment of Neurodegenerative Disorders with Thiourea Compounds | CLN6, MSR1, TPMT | RAB9A 1969/4885KMT2A 3288/4885CYP1A2 2864/4885 |
| US-20080096875-A1 | THIOUREA COMPOUNDS | TPMT, HAVCR2, ETV6 | RAB9A 2434/4885KMT2A 1846/4885CYP1A2 555/4885 |
| US-20080113975-A1 | THIOUREA COMPOUNDS | TPMT, HAVCR2, EIF2AK2 | RAB9A 2430/4885KMT2A 2203/4885CYP1A2 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.